Role of adipokines and cytokines in obesity-associated breast cancer: Therapeutic targets

Cytokine and Growth Factor Reviews

Volumn 24, Issue 6, 2013, Pages 503-513

  Khan, Sajid ^a   Shukla, Samriddhi ^a   Sinha, Sonam ^a   Meeran, Syed Musthapa ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Adiponectin; Breast cancer; Cytokines; Leptin; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMFEPRAMONE; BEVACIZUMAB; CYTOKINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ESTROGEN; FULVESTRANT; GEFITINIB; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAPATINIB; LEPTIN; LETROZOLE; LORCASERIN; METFORMIN; PHENDIMETRAZINE; PHENTERMINE; PITAVASTATIN; ROSCOVITINE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; TAMOXIFEN; TETRAHYDROLIPSTATIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; LIVER CANCER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASE; AMPK; BASIC FIBROBLAST GROWTH FACTOR; BFGF; BMI; BODY MASS INDEX; BREAST CANCER; C-JUN N-TERMINAL KINASE; C/EBPΑ; CCAAT/ENHANCER BINDING PROTEIN-Α; CDK; CLS; COX-2; CROWN-LIKE STRUCTURE; CYCLIN-DEPENDENT KINASE; CYCLOOXYGENASE-2; CYTOKINES; EGCG; EPIGALLOCATECHIN-3-GALLATE; ERK; ERΑ; ESTROGEN RECEPTOR-Α; EXTRACELLULAR SIGNAL-REGULATED KINASE; GLYCOGEN SYNTHASE KINASE-3Β; GSK-3Β; HB-EGF; HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR; HER-2; HIF-1Α; HTERT; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2; HUMAN TELOMERASE REVERSE TRANSCRIPTASE; HYPOXIA-INDUCIBLE FACTOR-1Α; IFNS; IGF BINDING PROTEINS; IGF-1R; IGFBPS; IGFS; ILS; INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR; INSULIN-LIKE GROWTH FACTORS; INTERFERONS; INTERLEUKINS; JAK2; JANUS KINASE-2; JNK; LDL; LEPTIN; LOW-DENSITY LIPOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; MTOR; NFΚB; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; NSAIDS; NUCLEAR FACTOR KAPPA-B; OBESITY; PARP; PDGF-BB; PEG-LPRA2; PEGYLATED LEPTIN PEPTIDE RECEPTOR ANTAGONIST 2; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Α; PFS; PLATELET-DERIVED GROWTH FACTOR SUBUNIT B HOMODIMER; POLY (ADP-RIBOSE) POLYMERASE; PPARΑ; PROGRESSION-FREE SURVIVAL; SEX HORMONE BINDING GLOBULIN; SHBG; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-3; SOCS3; STAT3; SUPPRESSOR OF CYTOKINE SIGNALING-3; TNF-Α; TUMOR NECROSIS FACTOR-Α; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VEGF; VEGF-R2;

ADIPOKINES; ANIMALS; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; OBESITY;

EID: 84888305648     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.10.001     Document Type: Short Survey

References (150)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Hulka B.S., Moorman P.G. Breast cancer: hormones and other risk factors. Maturitas 2001, 38:103-113. discussion 13-6.
3. Key J., Hodgson S., Omar R.Z., Jensen T.K., Thompson S.G., Boobis A.R., et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control 2006, 17:759-770.
4. Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Bouvard V., et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007, 8:292-293.
5. Donohoe C.L., Doyle S.L., Reynolds J.V. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 2011, 3:12.
6. Kanasaki K., Koya D. Biology of obesity: lessons from animal models of obesity. J Biomed Biotechnol 2011, 2011:197636.
7. Vainio H., Kaaks R., Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 2002, 11(Suppl. 2):S94-S100.
8. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
9. Rack B., Andergassen U., Neugebauer J., Salmen J., Hepp P., Sommer H., et al. The German SUCCESS C Study - The First European Lifestyle Study on breast cancer. Breast Care (Basel) 2010, 5:395-400.
10. Danaei G., Vander Hoorn S., Lopez A.D., Murray C.J., Ezzati M. (Cancers) CRAcg. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005, 366:1784-1793.
11. Carmichael A.R. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 2006, 113:1160-1166.
12. Abrahamson P.E., Gammon M.D., Lund M.J., Flagg E.W., Porter P.L., Stevens J., et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:1871-1877.
13. Porter G.A., Inglis K.M., Wood L.A., Veugelers P.J. Effect of obesity on presentation of breast cancer. Ann Surg Oncol 2006, 13:327-332.
14. Calle E.E., Thun M.J. Obesity and cancer. Oncogene 2004, 23:6365-6378.
15. Macciò A., Madeddu C., Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev 2009, 10:660-670.
16. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010, 61:301-316.
17. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
18. Renier G., Clément I., Desfaits A.C., Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology 1996, 137:4611-4618.
19. Heemskerk V.H., Daemen M.A., Buurman W.A. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev 1999, 10:5-14.
20. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y., Stratford A.L., et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246.
21. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
22. Chan B.T., Lee A.V. Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2008, 13:415-422.
23. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
24. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46:2347-2355.
25. Murano I., Barbatelli G., Parisani V., Latini C., Muzzonigro G., Castellucci M., et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008, 49:1562-1568.
26. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
27. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr Opin Pharmacol 2009, 9:351-369.
28. Subbaramaiah K., Howe L.R., Bhardwaj P., Du B., Gravaghi C., Yantiss R.K., et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011, 4:329-346.
29. Morris P.G., Hudis C.A., Giri D., Morrow M., Falcone D.J., Zhou X.K., et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011, 4:1021-1029.
30. Nicolini A., Carpi A., Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006, 17:325-337.
31. Macciò A., Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal 2011, 11:2020-2036.
32. Grisouard J., Dembinski K., Mayer D., Keller U., Müller B., Christ-Crain M. Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation. Diabetol Metab Syndr 2011, 3:16.
33. Zappalà G., Rechler M.M. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochem Biophys Res Commun 2009, 382:785-789.
34. Kim K.Y., Kim J.K., Jeon J.H., Yoon S.R., Choi I., Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005, 327:460-467.
35. Vona-Davis L., Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007, 14:189-206.
36. Collins S., Kuhn C.M., Petro A.E., Swick A.G., Chrunyk B.A., Surwit R.S. Role of leptin in fat regulation. Nature 1996, 380:677.
37. Lindheim S.R., Sauer M.V., Carmina E., Chang P.L., Zimmerman R., Lobo R.A. Circulating leptin levels during ovulation induction: relation to adiposity and ovarian morphology. Fertil Steril 2000, 73:493-498.
38. Green E.D., Maffei M., Braden V.V., Proenca R., DeSilva U., Zhang Y., et al. The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Genome Res 1995, 5:5-12.
39. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
40. Ahima R.S., Osei S.Y. Leptin signaling. Physiol Behav 2004, 81:223-241.
41. Hynes G.R., Jones P.J. Leptin and its role in lipid metabolism. Curr Opin Lipidol 2001, 12:321-327.
42. Huang L., Wang Z., Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem 2001, 276:6343-6349.
43. Hamilton B.S., Paglia D., Kwan A.Y., Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995, 1:953-956.
44. Harris H.R., Tworoger S.S., Hankinson S.E., Rosner B.A., Michels K.B. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res (Phila) 2011, 4:1449-1456.
45. Garofalo C., Koda M., Cascio S., Sulkowska M., Kanczuga-Koda L., Golaszewska J., et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006, 12:1447-1453.
46. Ishikawa M., Kitayama J., Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004, 10:4325-4331.
47. Cleary M.P., Phillips F.C., Getzin S.C., Jacobson T.L., Jacobson M.K., Christensen T.A., et al. Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 2003, 77:205-215.
48. Cleary M.P., Juneja S.C., Phillips F.C., Hu X., Grande J.P., Maihle N.J. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 2004, 229:182-193.
49. Bjørbaek C., Uotani S., da Silva B., Flier J.S. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997, 272:32686-32695.
50. Yin N., Wang D., Zhang H., Yi X., Sun X., Shi B., et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 2004, 64:5870-5875.
51. Saxena N.K., Vertino P.M., Anania F.A., Sharma D. leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 2007, 282:13316-13325.
52. Bjørbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998, 1:619-625.
53. Bjørbaek C., El-Haschimi K., Frantz J.D., Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999, 274:30059-30065.
54. Palianopoulou M., Papanikolaou V., Stefanou N., Tsezou A. The activation of leptin-mediated survivin is limited by the inducible suppressor SOCS-3 in MCF-7 cells. Exp Biol Med (Maywood) 2011, 236:70-76.
55. Park H., Kim M., Kwon G.T., Lim D.Y., Yu R., Sung M.K., et al. A high-fat diet increases angiogenesis, solid tumor growth, and lung metastasis of CT26 colon cancer cells in obesity-resistant BALB/c mice. Mol Carcinog 2011.
56. Garonna E., Botham K.M., Birdsey G.M., Randi A.M., Gonzalez-Perez R.R., Wheeler-Jones C.P. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One 2011, 6:e18823.
57. Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K., et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 2006, 281:26320-26328.
58. Kitawaki J., Kusuki I., Koshiba H., Tsukamoto K., Honjo H. Leptin directly stimulates aromatase activity in human luteinized granulosa cells. Mol Hum Reprod 1999, 5:708-713.
59. Falk R.T., Brinton L.A., Madigan M.P., Potischman N., Sturgeon S.R., Malone K.E., et al. Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat 2006, 98:157-165.
60. Fusco R., Galgani M., Procaccini C., Franco R., Pirozzi G., Fucci L., et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer 2010, 17:373-382.
61. Jardé T., Caldefie-Chézet F., Damez M., Mishellany F., Penault-Llorca F., Guillot J., et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 2008, 19:905-911.
62. Ozet A., Arpaci F., Yilmaz M.I., Ayta H., Ozturk B., Komurcu S., et al. Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol 2001, 31:424-427.
63. Catalano S., Mauro L., Marsico S., Giordano C., Rizza P., Rago V., et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004, 279:19908-19915.
64. Garofalo C., Sisci D., Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin Cancer Res 2004, 10:6466-6475.
65. Núñez N.P., Jelovac D., Macedo L., Berrigan D., Perkins S.N., Hursting S.D., et al. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Clin Cancer Res 2004, 10:5375-5380.
66. Geisler J., Lønning P.E., Krag L.E., Løkkevik E., Risberg T., Hagen A.I., et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006, 42:2968-2975.
67. Fiorio E., Mercanti A., Terrasi M., Micciolo R., Remo A., Auriemma A., et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008, 8:305.
68. Rahmati-Yamchi M., Zarghami N., Rahbani M., Montazeri A. Plasma leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer. Breast Cancer (Auckl) 2011, 5:27-35.
69. Ren H., Zhao T., Wang X., Gao C., Wang J., Yu M., et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2010, 394:59-63.
70. Chagnon Y.C., Wilmore J.H., Borecki I.B., Gagnon J., Pérusse L., Chagnon M., et al. Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab 2000, 85:29-34.
71. Mammès O., Betoulle D., Aubert R., Herbeth B., Siest G., Fumeron F. Association of the G-2548A polymorphism in the 5' region of the LEP gene with overweight. Ann Hum Genet 2000, 64:391-394.
72. Yiannakouris N., Yannakoulia M., Melistas L., Chan J.L., Klimis-Zacas D., Mantzoros C.S. The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability. J Clin Endocrinol Metab 2001, 86:4434-4439.
73. Terrasi M., Fiorio E., Mercanti A., Koda M., Moncada C.A., Sulkowski S., et al. Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells. Int J Cancer 2009, 125:1038-1044.
74. Cleveland R.J., Gammon M.D., Long C.M., Gaudet M.M., Eng S.M., Teitelbaum S.L., et al. Common genetic variations in the LEP and LEPR genes, obesity and breast cancer incidence and survival. Breast Cancer Res Treat 2010, 120:745-752.
75. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
76. Saito K., Tobe T., Yoda M., Nakano Y., Choi-Miura N.H., Tomita M. Regulation of gelatin-binding protein 28 (GBP28) gene expression by C/EBP. Biol Pharm Bull 1999, 22:1158-1162.
77. Bełtowski J., Jamroz-Wiśniewska A., Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2008, 8:7-46.
78. Yamauchi T., Hara K., Kubota N., Terauchi Y., Tobe K., Froguel P., et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003, 3:243-254.
79. Grossmann M.E., Nkhata K.J., Mizuno N.K., Ray A., Cleary M.P. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 2008, 98:370-379.
80. Jardé T., Caldefie-Chézet F., Goncalves-Mendes N., Mishellany F., Buechler C., Penault-Llorca F., et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009, 16:1197-1210.
81. Nakayama S., Miyoshi Y., Ishihara H., Noguchi S. Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat 2008, 112:405-410.
82. Miyoshi Y., Funahashi T., Kihara S., Taguchi T., Tamaki Y., Matsuzawa Y., et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003, 9:5699-5704.
83. Mantzoros C., Petridou E., Dessypris N., Chavelas C., Dalamaga M., Alexe D.M., et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89:1102-1107.
84. Chen D.C., Chung Y.F., Yeh Y.T., Chaung H.C., Kuo F.C., Fu O.Y., et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006, 237:109-114.
85. Hou W.K., Xu Y.X., Yu T., Zhang L., Zhang W.W., Fu C.L., et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007, 120:1592-1596.
86. Tworoger S.S., Eliassen A.H., Kelesidis T., Colditz G.A., Willett W.C., Mantzoros C.S., et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007, 92:1510-1516.
87. Kang J.H., Yu B.Y., Youn D.S. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007, 22:117-121.
88. Miyatani Y., Yasui T., Uemura H., Yamada M., Matsuzaki T., Kuwahara A., et al. Associations of circulating adiponectin with estradiol and monocyte chemotactic protein-1 in postmenopausal women. Menopause 2008, 15:536-541.
89. Combs T.P., Berg A.H., Rajala M.W., Klebanov S., Iyengar P., Jimenez-Chillaron J.C., et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003, 52:268-276.
90. Dieudonne M.N., Bussiere M., Dos Santos E., Leneveu M.C., Giudicelli Y., Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2006, 345:271-279.
91. Chen X., Wang Y. Adiponectin and breast cancer. Med Oncol 2011, 28:1288-1295.
92. Kim K.Y., Baek A., Hwang J.E., Choi Y.A., Jeong J., Lee M.S., et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 2009, 69:4018-4026.
93. Motoshima H., Wu X., Mahadev K., Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004, 315:264-271.
94. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-2898.
95. Wang Y., Lam K.S., Xu J.Y., Lu G., Xu L.Y., Cooper G.J., et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005, 280:18341-18347.
96. Schäffler A., Schölmerich J., Buechler C. Mechanisms of Disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Rev Endocrinol 2007, 3:345-354.
97. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007, 293:E1118-E1128.
98. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl. 5):10-17.
99. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999, 59:3915-3918.
100. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002, 277:38205-38211.
101. Seifeddine R., Dreiem A., Blanc E., Fulchignoni-Lataud M.C., Le Frère Belda M.A., Lecuru F., et al. Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells. Cancer Res 2008, 68:2158-2165.
102. Pal P., Lochab S., Kanaujiya J., Sanyal S., Trivedi A.K. Ectopic expression of hC/EBPs in breast tumor cells induces apoptosis. Mol Cell Biochem 2010, 337:111-118.
103. Johnston S.R. Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?. Breast Cancer Res Treat 2005, 93(Suppl. 1):S1-S2.
104. Margariti N., Fox S.B., Bottini A., Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. Breast Cancer Res Treat 2011, 128:599-606.
105. Alvarez R.H., Booser D.J., Cristofanilli M., Sahin A.A., Strom E.A., Guerra L., et al. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 2010, 116:1210-1217.
106. Sabnis G., Goloubeva O., Jelovac D., Schayowitz A., Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007, 13:2751-2757.
107. Jelovac D., Sabnis G., Long B.J., Macedo L., Goloubeva O.G., Brodie A.M. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005, 65:5380-5389.
108. Lorincz A.M., Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006, 13:279-292.
109. Wisierska-Gadek J., Gritsch D., Zulehner N., Komina O., Maurer M. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells. J Cell Biochem 2011, 112:761-772.
110. Shimizu M., Yasuda Y., Sakai H., Kubota M., Terakura D., Baba A., et al. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 2011, 11:281.
111. Menendez J.A., Vellon L., Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005, 16:1253-1267.
112. http://clinicaltrials.gov/ct2/show/NCT00944918%3Fterm=aromatase+inhibitors+phase+3%26rank=3.
113. Leo A.D., Biganzoli L., Bohm S., Lupi G., Oriana S., Riboldi G., et al. An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer. Tumori 1994, 80:443-447.
114. http://clinicaltrials.gov/ct2/show/NCT00241449%3Fterm=fulvestrant+in+postmenopausal+women+phase+3%26rank=14.
115. Chen J.Q., Brown T.R., Russo J. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta 2009, 1793:1128-1143.
116. Winder W.W., Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999, 277:E1-E10.
117. Rodgers R.J., Tschöp M.H., Wilding J.P. Anti-obesity drugs: past, present and future. Dis Model Mech 2012, 5:621-626.
118. Rene Gonzalez R., Watters A., Xu Y., Singh U.P., Mann D.R., Rueda B.R., et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009, 11:R36.
119. Otvos L., Haspinger E., La Russa F., Maspero F., Graziano P., Kovalszky I., et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 2011, 11:90.
120. http://clinicaltrials.gov/ct2/show/NCT00201773%3Fterm=celecoxib+phase+2+clinical+trial+in+postmenopausal+women%26rank=2.
121. http://clinicaltrials.gov/ct2/show/NCT00933309%3Fterm=exemestane%2C+avandamet%26rank=1.
122. http://clinicaltrials.gov/ct2/show/NCT00073073%3Fterm=celecoxib+postmenopausal+breast+cancer+phase+2%26rank=3.
123. http://clinicaltrials.gov/ct2/show/NCT00112749%3Fterm=infliximab+breast+cancer+phase+2%26rank=1.
124. http://clinicaltrials.gov/ct2/show/NCT01127867%3Fterm=dha+breast+cancer%26rank=2.
125. http://clinicaltrials.gov/ct2/show/NCT00917735%3Fterm=green+tea+extract+breast+cancer%26rank=1.
126. http://clinicaltrials.gov/ct2/show/NCT00516243%3Fterm=green+tea+extract+breast+cancer%26rank=2.
127. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71:1397-1421.
128. Zhou H., Luo Y., Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010, 10:571-581.
129. Shehzad A., Khan S., Sup Lee Y. Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol 2012, 8:179-190.
130. Aggarwal B.B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010, 30:173-199.
131. Ghanim H., Sia C.L., Abuaysheh S., Korzeniewski K., Patnaik P., Marumganti A., et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010, 95:E1-E8.
132. Morselli E., Maiuri M.C., Markaki M., Megalou E., Pasparaki A., Palikaras K., et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis 2010, 1:e10.
133. Lanzilli G., Fuggetta M.P., Tricarico M., Cottarelli A., Serafino A., Falchetti R., et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol 2006, 28:641-648.
134. Zhang X., Chen L.X., Ouyang L., Cheng Y., Liu B. Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif 2012, 45:466-476.
135. Pratheeshkumar P., Sreekala C., Zhang Z., Budhraja A., Ding S., Son Y.O., et al. Cancer prevention with promising natural products: mechanisms of action and molecular targets. Anticancer Agents Med Chem 2012, 12:1159-1184.
136. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996, 2:659-668.
137. De Angel R.E., Smith S.M., Glickman R.D., Perkins S.N., Hursting S.D. Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. Nutr Cancer 2010, 62:1074-1086.
138. Kanjoormana M., Kuttan G. Antiangiogenic activity of ursolic acid. Integr Cancer Ther 2010, 9:224-235.
139. Hwang J.T., Park I.J., Shin J.I., Lee Y.K., Lee S.K., Baik H.W., et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 2005, 338:694-699.
140. Naaz A., Yellayi S., Zakroczymski M.A., Bunick D., Doerge D.R., Lubahn D.B., et al. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 2003, 144:3315-3320.
141. Zhang M., Ikeda K., Xu J.W., Yamori Y., Gao X.M., Zhang B.L. Genistein suppresses adipogenesis of 3T3-L1 cells via multiple signal pathways. Phytother Res 2009, 23:713-718.
142. Grove K.A., Sae-tan S., Kennett M.J., Lambert J.D. (-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. Obesity (Silver Spring) 2012, 20:2311-2313.
143. Kim H., Hiraishi A., Tsuchiya K., Sakamoto K. (-)-Epigallocatechin gallate suppresses the differentiation of 3T3-L1 preadipocytes through transcription factors FoxO1 and SREBP1c. Cytotechnology 2010, 62:245-255.
144. Klaus S., Pültz S., Thöne-Reineke C., Wolfram S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int J Obes (Lond) 2005, 29:615-623.
145. Ross S.A. Evidence for the relationship between diet and cancer. Exp Oncol 2010, 32:137-142.
146. Cho S.Y., Park P.J., Shin H.J., Kim Y.K., Shin D.W., Shin E.S., et al. (-)-Catechin suppresses expression of Kruppel-like factor 7 and increases expression and secretion of adiponectin protein in 3T3-L1 cells. Am J Physiol Endocrinol Metab 2007, 292:E1166-E1172.
147. Si H., Fu Z., Babu P.V., Zhen W., Leroith T., Meaney M.P., et al. Dietary epicatechin promotes survival of obese diabetic mice and Drosophila melanogaster. J Nutr 2011, 141:1095-1100.
148. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
149. Lee S.H., Kim B., Oh M.J., Yoon J., Kim H.Y., Lee K.J., et al. Persicaria hydropiper (L.) spach and its flavonoid components, isoquercitrin and isorhamnetin, activate the Wnt/β-catenin pathway and inhibit adipocyte differentiation of 3T3-L1 cells. Phytother Res 2011, 25:1629-1635.
150. Chang C.J., Tzeng T.F., Liou S.S., Chang Y.S., Liu I.M. Myricetin increases hepatic peroxisome proliferator-activated receptor α protein expression and decreases plasma lipids and adiposity in rats. Evid Based Complement Alternat Med 2012, 2012:787152.